Abstract. The aim of this study is to examine the association between low serum vitamin B12 levels and low serum vitamin D levels and cochlear health in women. A prospective case–control study was carried out in the Department of Otolaryngology, Malatya Training and Research Hospital between 2017–2018. Thirty (30) patients with vitamin B12 deficiency (a mean age of 32.5 ± 1.7 years(y) women); 30 patients with vitamin D deficiency (a mean age of 32.3 ± 1.58 y women) and 30 controls (a mean age of 27.8 ± 1.48 y women) were recruited. The study participants have no evidence of symptomatic hearing loss. Transiently evoked otoacoustic emissions (TEOAEs) and distortion product otoacoustic emissions (DPOAEs) of the study participants were recorded. A comparative analysis of the parameters revealed that results at TEOAE 1,2,3,4 kHz (p = 0.013, p = 0.002, p = 0.001, p = 0.001, respectively) and at DPOAE 1, 2, 6 kHz ( p < 0.001, p < 0.001, p = 0.002, respectively) were somewhat lower in patients with vitamin B12 deficient group when compared with the controls. Moreover, TEOAE 3,4 kHz (p = 0.005, p = 0.013 respectively) and DPOAE 1,2,6 kHz (p = 0.005, p = 0.01, p = 0.031, respectively) were lower in the vitamin D deficiency group compared with the controls. There was a significant association between both vitamin B12 deficiency and vitamin D deficiency and cochlear health. Patients with vitamin B12 and vitamin D deficiency should be evaluated for cochlear function.
Objectives Acute ischemic stroke is a common cause of mortality and morbidity worldwide. Percutaneous endovascular intervention is an important treatment method in ischemic stroke. Endovascular procedure success is associated with the clinical outcome of the patients. The CHA2DS2‐VASC score is an important score used to determine the risk of ischemic stroke in patients with atrial fibrillation. In our study, we aimed to evaluate the relationship between procedure success and CHA2DS2‐VASC score in patients with acute ischemic stroke who underwent endovascular intervention. Materials and methods A total of 102 consecutive patients who underwent endovascular intervention with acute ischemic stroke were included in the study. The admission CHA2DS2‐VASc scores of the patients were recorded. After the procedure, the relationship between the TICI score and the CHA2DS2‐VASc score was evaluated. Results CHA2DS2‐VASc score was significantly higher in the group that resulted in unsuccessful endovascular intervention (2.78 ± 1.44, 5.02 ± 1.77 p < .001). Receiver‐operating characteristics analysis revealed the cutoff value of CHA2DS2‐VASc score ≥3 as a predictor of unsuccessful intervention with 76,6% sensitivity and 83,3% specificity, positive predictive value 50%, negative predictive value 84,6% (area under the curve [AUC]: 0.827,95% CI: 0.739–0.895, p < .001). In the multivariate analysis; atrial fibrillation ([β] = 4.201; [CI]: 1.251–14.103, p = .020), CHA2DS2‐VASc score ([β] = 0.053; [CI]: 0.004–0.750, p = .030) were found independent predictors for unsuccessful intervention treatment. Conclusions In our study, we showed that the CHA2DS2‐VASc score is associated with the success of endovascular intervention in patients with acute ischemic stroke who underwent percutaneous endovascular treatment.
Background Hyperglycemia during acute ischemic stroke is associated with worse outcomes, and this glucose altitude may persist in the initial days. In this study, we investigate the effect of glucose fluctuations in the first 4 days in patients diagnosed with acute ischemic stroke and who underwent ivr-tPA ± interventional thrombectomy or only interventional thrombectomy on stroke prognosis. Study was designed bicentered retrospective case series. Patients older than 18 years were included and those suitable for acute treatment, treatment indications, contraindications, and treatment management of hyperglycemia were selected according to the 2018 American Stroke Association guidelines. The effect of fasting glucose values of patients in the first 4 days on admission and 24th hour NIHSS scores, duration of hospitalization, disability, mortality, and prognosis were analyzed. We aimed to demostred the effect of the first 4-day glucose values measured in patients treated in a stroke center on clinical prospect. Results One hundred and seventy-six patients were included in the study. Group 1 included 30 (17%) patients with severe clinical condition (NIHSS at admission ≥ 16), and Group 2 comprised 146 (83%) patients with moderate and mild clinical condition (NIHSS at admission < 16). The glucose values of Groups 1 and 2 were found as follows: day 1 (admission): 178.7 ± 10.3 mg/dl and 138.3 ± 54.9 mg/dl, day 2: 197.7 ± 99.8 mg/dl and 137.6 ± 51.8 mg/dl, day 3: 186.1 ± 97.6 mg/dl and 127.5 ± 50.0 mg/dl, and day 4: 169.2 ± 85.0 mg/dl and 126.7 ± 49.3 mg/dl (p < 0.05). Mortality risk of patients with glucose ≥ 200 mg/dl was 43.5% on day 1 (p > 0.05), 57.1% on day 2, 68.4% on day 3, and 76.5% on day 4 (p < 0.05). Conclusions The glucose level of patients in severe clinical condition peaked on the second day and that 4 days of resilient severe hyperglycemia is a negative risk factor for sequela and mortality.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.